HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will...
Hence then, the article about ascletis announces poster presentations on the study results of asc30 and asc47 at the 85th scientific sessions of american diabetes association ada was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) )
Also on site :
- Witney Carson Claps Back at ‘DWTS’ Judge Carrie Ann Inaba, Joining Uproar Over Comments on Guillermo Rodriguez: ‘I Said What I Said’
- Disney Cruise Line Offers First Look Inside Disney Believe with New Frozen Dining, Encanto Show, and Themed Lounges
- Tom DeLonge Was in the Crowd When 43,000 Fans Serenaded Him With His Own Song: ‘He Was Definitely in His Feels’